Osimertinib-chemo combo boosts progression-free survival in EGFR-mutated lung cancer: study
But the combination regimen was associated with higher rate of treatment-related adverse events, doctors say.
Adding chemotherapy to oral osimertinib in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer prolongs progression-free survival by up to nine months, research shows.
US and French-led doctors say this benefit appeared consistent across patient subgroups, including those with either EGFR mutation type and with or without CNS metastases at baseline.
